Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01885338 · ClinicalTrials.gov registry record · Phase 1
N-acetylcysteine (NAC) for Improving Cognitive Dysfunction in Schizophrenia
A Phase 1 study, sponsored by VA Greater Los Angeles Healthcare System.
- Completed
- Registry status
- Phase 1
- Development phase
- 26
- Enrollment target
NCT01885338 is a Phase 1 study that has completed, run by VA Greater Los Angeles Healthcare System. The registered enrollment target is 26 participants.
The verdict
NCT01885338, a Phase 1 study, has completed, sponsored by VA Greater Los Angeles Healthcare System.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 26 participants
- Enrollment target
Study Summary
This study will evaluate the effect of the dietary supplement N-acetylcysteine (NAC) on electrophysiologic (EEG) markers related to cognition, as well as performance on psychological tests measuring cognition. The primary hypothesis is that participants treated with NAC will show improvements in cognitive function, as measured by EEG and performance-based tests.
Interventions
- DRUG N-acetylcysteine (NAC)
- DRUG Inactive placebo capsule
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2013-06 |
| Est. Completion | 2014-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01885338
The ClinicalTrials.gov registry entry for NCT01885338 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is VA Greater Los Angeles Healthcare System, which has 23 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which N-acetylcysteine (NAC) is the first listed.
NCT01885338 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01885338 about?
NCT01885338 is a clinical study titled "N-acetylcysteine (NAC) for Improving Cognitive Dysfunction in Schizophrenia". This study will evaluate the effect of the dietary supplement N-acetylcysteine (NAC) on electrophysiologic (EEG) markers related to cognition, as well as performance on psychological tests measuring cognition. The primary hypothesis is that participants treated with NAC will show improvements in cog...
What is the current status of trial NCT01885338?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2013-06. Estimated completion is 2014-05.
What interventions are being tested in trial NCT01885338?
The interventions under investigation include: N-acetylcysteine (NAC) (DRUG), Inactive placebo capsule (DRUG).
Who is sponsoring clinical trial NCT01885338?
This trial is sponsored by VA Greater Los Angeles Healthcare System, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.